Veterinary Medicine

Dechra Targets 2027 for First Ready-to-Use Pet Cell Therapy via Gallant
Dechra has completed its acquisition of biotechnology firm Gallant Pet to integrate off-the-shelf mesenchymal stromal cell therapies into its veterinary portfolio.